Navigation Links
Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014
Date:7/21/2014

;                          9373657.

About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-Hepatitis, or NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.


'/>"/>
SOURCE Galmed Pharmaceuticals Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  CryoLife, Inc. (NYSE: ... tissue processing company focused on cardiac and vascular surgery, ... President and Chief Executive Officer, has been elected to ... Steven G. Anderson , Executive Chairman ... has proven to be an excellent leader who is ...
(Date:10/22/2014)... 2014  Early symptoms of diabetic eye and ... new technology, coupled with yearly, comprehensive eye exams, ... detection of eye diseases, including those associated with ... left untreated, these diseases can potentially lead to ... Recently, optometric researchers have deployed a new tool ...
(Date:10/22/2014)... 2014 InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) ... revolutionizing spinal cord injury (SCI) treatment with their novel ... in tissue regrowth in the spinal cord area when ... FDA approved polymer, the scaffold ultimately breaks down to ... human body. NVIV has recently attracted significant investor attention ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... 2a Clinical Trial at UCSD, NOVATO, ... or the "Company") (OTC Bulletin Board:,RPTP), today ... (the,"Agreement") with the University of California, San ... trial to evaluate a delayed-release preparation,of cysteamine ...
... Corporation, a,Georgia-based biotech company, announced today a ... collaboration with Cato Research Ltd.,its global contract ... will help support continued development of Abeome,s ... vastly improves the development of,monoclonal antibodies and ...
Cached Medicine Technology:Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 2Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 3Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 4Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 5Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Hay House is ... Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written by ... Yoga & Recovery. This book is meant to help ... a life of recovery. , Recovery 2.0 is not ... Steps; Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... access to serve offshore health needs by video ... first full-service offshore medical product using video telemedicine, ... industry - securing physician staffing for 24/7/365 services ... services are provided by emergency medicine and internal ...
... Co., Inc., (NYSE Amex: TPI ), a ... in Chengdu, China, today,announced that management will hold a ... 11:00 a.m. EDT on Friday, May 15, 2009. Financial,results ... market closes. , Interested parties ...
... behalf of 1.275 million Americans living with spinal cord injurySHORT ... Foundation today announced Matthew Reeve, son of Christopher Reeve and ... will run the 2009 ING New York City Marathon. Running ... compete on behalf of the 1.275 million Americans living with ...
... 50 with prostate cancer, undergoing a radical prostatectomy can ... a new study from Henry Ford Hospital. , Results ... show that the surgical procedure improves the 5-, 10-, ... with other standard treatments such as radiotherapy or watchful ...
... embryonic stem cells are recognized as a potential treatment ... injury (SCI). However, in studies using embryonic stem cells ... been the development of tumors following transplantation. , ... (Vol. 18 No.1), a team of Japanese researchers ...
... Palomar Medical Technologies, Inc. (Nasdaq: PMTI ), ... cosmetic treatments, announced today that it has entered into ... leading manufacturer of solid state lasers, for Quantel,s SINON(TM) ... United States and Canada.The SINON Q-switched ruby laser was ...
Cached Medicine News:Health News:The Doctor Is In, Around the Clock 2Health News:The Doctor Is In, Around the Clock 3Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Third Quarter Earnings Conference Call on Friday, May 15, 2009 at 11:00 a.m. EDT 2Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 2Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 3Health News:Surgery improves survival for prostate cancer patients younger than 50 2Health News:Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors 2Health News:Palomar Medical to Market Quantel's SINON Tattoo Removal Laser in the United States and Canada 2Health News:Palomar Medical to Market Quantel's SINON Tattoo Removal Laser in the United States and Canada 3Health News:Palomar Medical to Market Quantel's SINON Tattoo Removal Laser in the United States and Canada 4
... to end transcription services. Zodiac offers ... be either submitted over the phone ... call 24 hours a day, 7 ... be recorded on a digital handheld ...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
... Catering to the special needs ... Infant ThermoWrap™ protects the littlest ... their most vulnerable by providing ... continuous management of an infants ...
The under-patient design of the pediatric full access blanket warms even the tiniest patients while allowing full access for surgeons and staff....
Medicine Products: